JK-08

N/A

Report date: 2022/11/21 20:00:38

Base Information

Drug NameJK-08

Drug Alias NameIL15/IL15RA complex-anti CTLA-4 antibody fusion proteinJK-08

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAnti-CTLA4Interleukin-15 receptors agonists

TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Interleukin-15 receptors

Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[19]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumSpainEU

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesXinlitai (Chengdu) Biological Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSalubris Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[19]

Inactive IndicationsN/A

Other Information

ATC CodeN/A